Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Cinis Fertilizer’s nomination committee ahead of the 2024 Annual General Meeting

The composition of the nomination committee in Cinis Fertilizer AB is hereby announced ahead of the 2024 Annual General Meeting.The nomination committee consists of the following members appointed by the largest shareholders, based on voting rights, as per 30 September 2023, as well as the Chairman of the Board: · Frederik Nilner, appointed by shareholder Jakob Liedberg (36.4% of votes and capital as of 30 September 2023) · Thomas Ranje, representing himself (15.5% of votes and capital as of 30 September 2023) · Morgan Sadarangani, appointed by shareholder Molindo Energy AB (3.5%

UPM closes Plattling mill in Germany – Participation process with employee representatives concluded

(UPM, Helsinki, 20 October 2023 at 12:30 EEST) – In July UPM Communication Papers announced plans to permanently close its Plattling mill in Germany to align graphic paper capacity to the customer demand. The participation process with the employee representatives has now been completed and the mill will cease its production latest by the end of November 2023. The number of UPM employees affected is 401. Graphic paper production on the two machines is expected to end on 15 November (PM 11) and on 22 November (PM 1), reducing the coated and uncoated publication paper capacity by 595,000

Boliden resolves to repurchase its treasury shares

The Board of Directors of Boliden has, based on the authorization from the Annual General Meeting on 25 April 2023, resolved to repurchase a maximum of 40,000 treasury shares on Nasdaq Stockholm during the period 20 October 2023 up to and including 27 October for a total amount of maximum SEK 13.2 million. The purpose of the repurchase is to ensure future delivery of shares to the participants in Boliden's long-term share saving programme (LTIP 2023/2026) as resolved by the Annual General Meeting 2023. The repurchase of shares will be carried out in accordance with the Market Abuse

Stable position for Södra despite prevailing market conditions

Södra posted a lower result for the third quarter of 2023. The result is stable in view of market conditions and in line with Södra’s expectations.In the third quarter of 2023, net sales for the Södra Group amounted to SEK 6,545 million (8,102), down 19 percent. Operating profit totalled SEK 410 million, compared with SEK 2,480 million in the year-earlier period. Return on capital employed was 12 percent (41) and the equity ratio was 61 percent. During the quarter, the World-class Efficiency project delivered on the annual efficiency gains, which currently total more than SEK 680 million

Probi AB (publ) appoints new CFO

Probi AB (publ), a leading provider of probiotic solutions, is pleased to announce the appointment of Per Lindblad as the company's new CFO. Per will start his assignment by the 1[st] of November, 2023. "We are delighted to welcome Per to the Probi team," said Anita Johansen, CEO of Probi. "With his extensive experience from specialty ingredients industries, including probiotics, and his solid expertise as a finance business partner, we are confident that he will help us achieve our strategic objectives." Per joins Probi from ABF Ingredients where he served as CFO. Previous to ABF

Ahlsell joins the Science Based Target initiative

As an important step in the sustainability work and with the aim of being a leading player in the climate transition, Ahlsell has committed to setting climate goals in line with the Science Based Targets initiative (SBTi).SBTi is a global organization that enables companies to set ambitious emission reduction targets in line with the latest climate science. The organization focuses on getting companies around the world to halve their emissions by 2030 and achieve net zero emissions by 2050. Through this commitment, Ahlsell will develop and report its targets. Ahlsell will develop both

Invitation to Medicover’s results presentation for Q3 2023

Medicover’s (MCOV B) Q3 report 2023 will be published on 3 November at 07.45 CET. The Company will hold a conference call (in English) for media, financial analysts and investors at 09.30 CET. The report will be presented by CEO Fredrik Rågmark and CFO Joe Ryan and followed by a question-and-answer session. Shortly before the webcast, presentation slides will be available on medicover.com . To access live webcast register here . To dial in and ask questions register here 

Studsvik’s Interim Report for the Third Quarter 2023

· The operating profit for the Group was SEK 22.9 million compared with SEK 26.1 million in the previous year. · High capacity utilization in Decommissioning and Radiation Protection Services. · During the quarter the Waste Management Technology business area signed a strategic agreement with GNS in Germany for treatment of waste. · Sale of an area of land on the Studsvik site was completed in the quarter with an impact on earnings of SEK 5.0 million. · Studsvik has entered into a cooperation agreement with Kärnfull Next to carry out a feasibility study aimed at investigating

Studsvik’s Board Chair becomes Working Chair

Jan Bardell, who was appointed as Studsvik’s Chair of the Board at the Annual General Meeting on April 24, 2023, will become the Working Chair of the Board, part time, as of October 20.The purpose of the change is that Bardell will work actively on the enquiries Studsvik has received about building Small Modular Reactors (SMRs) on the Studsvik site, outside Nyköping. Jan Bardell has been a member of the Board of Studsvik since 2022. For further information please contact: Jan Bardell, tel +46 768 60 84 06, jan.bardell@studsvik.com, or Camilla Hoflund, President and CEO, tel +46

Voi offers e-scooter rides for free to help clean up cities on International Climate Action Day

Riding a Voi e-scooter. Credit: Voi Shared e-scooter company Voi is offering free rides to help reduce emissions in towns and cities to mark International Climate Action Day 2023. New riders in Cambridge, Cheltenham, Corby, Gloucester, Kettering, Liverpool, London, Northampton, Oxford, Portsmouth, Rushden & Higham Ferrers, Southampton and Wellingborough can take advantage of a free 30 minute e-scooter use valid from Climate Action Day, 24 October, until 31 December with code CLIMATEACTION23. The introduction of Voi e-scooters and e-bikes into the UK has reduced carbon

ARTE COLLECTUM I AB (PUBL) IS AN ARTICLE 9 FUND

PRESS RELEASE20 October 2023, at 10:00 – Stockholm.Arte Collectum I AB (publ)www.artecollectum.comArte Collectum I AB (publ), reg. no. 559350-6909, (”Fund”), has been self-classified by AIFM Group AB, the Fund’s AIFM, as an Article 9 fund under SFRD (2019/2088), it is also labelled a dark green fund. The Fund has sustainable investments as its objective with the promotion of social characteristics according to SFDR. The classification has been made based on the legal development within the area of sustainability.Please find our Sustainability At a Glance attached and at www.

Invitation to phone conference with webcast in conjunction with the release of the Instalco Q3 2023 report

Instalco will release its Interim report Q3 2023 on 27 October at 07:30 CET. Instalco will also be presenting the report in a phone conference with webcast at 09:30 on the same day.Robin Boheman, CEO and Christina Kassberg, CFO will present and comment on the report. The conference will be held in English.     Publication of the interim report at 07:30 CEThttps://instalco.se/en/investors/financial-reports   Link to the webcast, 09:30 CEThttps://ir.financialhearings.com/instalco-q3-report-2023   Teleconference at 09:30 CEThttps://conference.financialhearings.com/

DarkGate attacks linked to Vietnam-based cyber criminals

WithSecure researchers tie recent DarkGate attacks in the UK, US, and India back to threat actors known for stealing information to hijack Meta Business accounts. Helsinki, Finland – October 20, 2023: WithSecure ™ (formerly known as F-Secure Business) researchers have tracked attacks using DarkGate malware to an active cluster of cyber criminals operating out of Vietnam. DarkGate is a Remote Access Trojan (RAT) that has been used in attacks since at least 2018 and is currently available to cyber criminals as Malware-as-a-Service (MaaS). It has a

Glycerol phenylbutyrate granted orphan drug designation for treatment of STXBP1 developmental and epileptic encephalopathy

Stockholm, October 20, 2023 – Immedica today announces that the European Commission has granted an orphan designation for glycerol phenylbutyrate in STXBP1 developmental and epileptic encephalopathy (STXBP1-DEE), following positive opinion from EMA’s Committee for Orphan Medicinal Products (COMP). Orphan designation is granted to medicines that treat, prevent, or diagnose a life-threatening or chronically debilitating rare disease, with a prevalence in the EU of below 5 in 10,000, and with either no satisfactory method of diagnosis, prevention or treatment or with significant benefit to

BioStock: WntResearch recruits first patient in restart of NeoFox

After receiving the green light for its redesigned study plan for NeoFox this summer, WntResearch have announced the recruitment of the first patient. The revised study is now officially underway with the first part expected to take about six months to complete. BioStock contacted CEO Pernilla Sandwall for a comment on this milestone.Read the article at biostock.se: https://www.biostock.se/en/2023/10/wntresearch-rekryterar-forsta-patienten-i-aterstarten-av-neofox/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

BioStock: Positive preclinical results for Curasight in lung cancer

Biotech company Curasight recently announced positive preclinical results for uTREAT in the treatment of non-small cell lung cancer, showing that uTREAT effectively inhibits tumor growth. These findings comes on the heels of recent positive preclinical results in the treatment of glioblastoma, reinforcing the hypothesis that uTREAT is not cancer type specific, but has the potential to treat a broader spectrum of solid tumors.Read the interview with Curasights CEO Ulrich Krasilnikoff at biostock.se: https://www.biostock.se/en/2023/10/positive-preclinical-results-for-curasight-in-lung-

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 174 - 20 OCTOBER 2023 In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 112/23 and 113/23.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Stig Frederiksen, Head of Investor Relations, tel.: +45 32 71 08 55, e-mail: sfr@norden.com

TradeVenue releases first analysis on White Pearl Technology Group

Swedish investor community, TradeVenue, released an in-depth analysis of the global IT-service provider, White Pearl Technology Group (WPTG) listed on Nasdaq First North Growth Market since the 29[th] of June 2023. The report highlights a significant upside potential in the consistent growth of WPTG."We have today published an initiating report on White Pearl Technology Group (WPTG). WPTG is an extremely fast-growing Group offering a comprehensive portfolio of solutions including IT consulting, infrastructure services, proprietary software products, system integration, cybersecurity, cloud

Preliminary results from Booster trial with Diamyd® provide additional support for intralymphatic injections

Preliminary results from the open-label clinical trial DIAGNODE-B provide additional support for the safety and feasibility of intralymphatic booster injections of Diamyd[®], showing only a small decline in stimulated endogeous insulin production one year following the additional injection and up to 8 years from type 1 diabetes diagnosis.“These results are valuable as they continue to support the feasibility of additional intralympahtic injections of Diamyd and a mild disease progression”, says Johnny Ludvigsson, Professor at Linköping University and Sponsor's representative of the trial.

Smoltek answers questions after investor event in Lund on October 9

This press release is an English version of the previously published Swedish version, which has interpretive precedence. Smoltek Nanotech Holding AB ("Smoltek") follows up the presentation at the investor event, Aktiedagen in Lund on October 9, with a post on the company's IR blog where CEO Håkan Persson answers questions about the content of the presentation.“The investor event Aktiedagen is a good opportunity for us to tell how we see our market, both demand and competition, as well as tell how we intend to commercialize our technology. But it is not possible to go in-depth in just

Lindex accelerates circularity with new textile-to-textile fibre

Lindex takes further steps and accelerates its commitment to circularity through a long-term agreement with Finnish Infinited Fiber Company and its patented fibre Infinna™, made from 100 per cent post-consumer textile waste. Partnering with Infinited Fiber is an important step in Lindex’s transformation to a more sustainable and circular assortment with raw material from textile waste. ‘With only a fraction of all textile waste in the world being recycled there must be a change and we are happy to see players like Infinited Fiber enabling this. Infinited Fiber has the technology

Aiforia initiates path to secure its first regulatory approval in the United States – application to the FDA anticipated in 2024

Aiforia Technologies Plc, Press Release, October 20, 2023 at 10:00 a.m. EEST. Aiforia Technologies Plc initiates a path to secure regulatory approval for its first product in the United States.The Food and Drug Administration (FDA) is responsible for market surveillance of medical devices in the U.S. Together with a local consulting company, Aiforia is planning and implementing the necessary steps to submit an application to the FDA during 2024.   “The demand for digital pathology image analysis in clinical diagnostics is increasing in the U.S. We want to ensure that we are well

Publishing of Stockmann’s Interim Management Statement for January–September 2023

STOCKMANN plc, Press release 20.10.2023 at 10:00 EEST Publishing of Stockmann’s Interim Management Statement for January–September 2023 Stockmann plc will publish its Interim Management Statement for January–September 2023 on Friday 27 October 2023 at 8:00 EEST. A press and analyst briefing will be held in English the same day at 10:00 EEST as a live webcast that can be followed via this link.  The recording and presentation material will be available on the company's website after the event. Further information:

Lytix Biopharma to host webcast after release of preliminary data from ATLAS-IT-05

Oslo, 20 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that Øystein Rekdal, Chief Executive Officer, and Graeme Currie, Chief Development Officer, will host a webcast for investors and analysts on Monday October 23 at 15:30 CET, in conjunction with the ESMO 2023 Congress.The webcast is being held to provide further insights and additional information about the preliminary data from the ATLAS-IT-05 study, that is being presented in a poster session at ESMO, and the associated press release

There are no items matching the current filter
There are no more items matching the current filter
Back to top